868 related articles for article (PubMed ID: 27387828)
1. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
3. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
4. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
7. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
Galkin A; Chen Y; Guenaga J; O'Dell S; Acevedo R; Steinhardt JJ; Wang Y; Wilson R; Chiang CI; Doria-Rose N; Grishaev AV; Mascola JR; Li Y
J Immunol; 2020 Mar; 204(6):1543-1561. PubMed ID: 32066595
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
10. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
11. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
12. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
Huang J; Kang BH; Pancera M; Lee JH; Tong T; Feng Y; Imamichi H; Georgiev IS; Chuang GY; Druz A; Doria-Rose NA; Laub L; Sliepen K; van Gils MJ; de la Peña AT; Derking R; Klasse PJ; Migueles SA; Bailer RT; Alam M; Pugach P; Haynes BF; Wyatt RT; Sanders RW; Binley JM; Ward AB; Mascola JR; Kwong PD; Connors M
Nature; 2014 Nov; 515(7525):138-42. PubMed ID: 25186731
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
[TBL] [Abstract][Full Text] [Related]
14. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
[TBL] [Abstract][Full Text] [Related]
15. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
16. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
[TBL] [Abstract][Full Text] [Related]
17. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
18. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
19. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
[TBL] [Abstract][Full Text] [Related]
20. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
